Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 115Squamous Cell Carcinoma of Head and Neck 61Triple Negative Breast Neoplasms 57Melanoma 54Lung Neoplasms 49Neoplasm Metastasis 48Breast Neoplasms 41Neoplasms 36Colorectal Neoplasms 35Head and Neck Neoplasms 25Endometrial Neoplasms 25Carcinoma, Renal Cell 24Uterine Cervical Neoplasms 21Stomach Neoplasms 21Ovarian Neoplasms 21Carcinoma, Transitional Cell 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 16Recurrence 15Carcinoma, Hepatocellular 14Pancreatic Neoplasms 13Sarcoma 12Carcinoma, Squamous Cell 12Glioblastoma 11Esophageal Squamous Cell Carcinoma 11Carcinoma 11Prostatic Neoplasms 10Brain Neoplasms 10Carcinoma, Merkel Cell 9

Interventions

pembrolizumab 2Carboplatin 2tislelizumab 1aumolertinib 1anlotinib 1aflutinib 1Platinum Compounds 1Pemetrexed 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Advanced Non-small Cell Lung Cancer × pembrolizumab × Clear all
NCT06452277 2026-05-18

SOHO-02

Bayer

Phase 3 Recruiting
444 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1 Recruiting
288 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡